Brokerages Set Centessa Pharmaceuticals plc (NASDAQ:CNTA) Target Price at $26.00

Centessa Pharmaceuticals plc (NASDAQ:CNTA) has been given a consensus recommendation of “Buy” by the seven brokerages that are presently covering the firm, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have covered the stock in the last year is $26.00.

CNTA has been the subject of several analyst reports. TD Cowen initiated coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating for the company. Guggenheim reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, General Counsel Iqbal J. Hussain sold 6,000 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total value of $91,740.00. Following the transaction, the general counsel now owns 118,265 shares of the company’s stock, valued at approximately $1,808,271.85. This represents a 4.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Saurabh Saha sold 55,000 shares of the company’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $17.44, for a total value of $959,200.00. Following the completion of the transaction, the chief executive officer now directly owns 520,661 shares in the company, valued at $9,080,327.84. This represents a 9.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 247,168 shares of company stock valued at $4,138,928 over the last quarter. Corporate insiders own 11.59% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new position in shares of Centessa Pharmaceuticals in the fourth quarter valued at $31,000. Woodline Partners LP grew its position in Centessa Pharmaceuticals by 5.7% during the 4th quarter. Woodline Partners LP now owns 545,645 shares of the company’s stock worth $9,140,000 after purchasing an additional 29,266 shares in the last quarter. Squarepoint Ops LLC grew its position in Centessa Pharmaceuticals by 33.2% during the 4th quarter. Squarepoint Ops LLC now owns 26,806 shares of the company’s stock worth $449,000 after purchasing an additional 6,685 shares in the last quarter. Stempoint Capital LP grew its position in Centessa Pharmaceuticals by 667.3% during the 4th quarter. Stempoint Capital LP now owns 641,964 shares of the company’s stock worth $10,753,000 after purchasing an additional 558,302 shares in the last quarter. Finally, Shay Capital LLC purchased a new position in Centessa Pharmaceuticals during the 4th quarter worth approximately $239,000. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ CNTA opened at $17.20 on Thursday. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a 50 day simple moving average of $16.46 and a 200-day simple moving average of $16.34. The company has a market cap of $2.27 billion, a PE ratio of -11.24 and a beta of 1.54. Centessa Pharmaceuticals has a 12-month low of $7.75 and a 12-month high of $19.09.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.